PASADENA, Calif.--(BUSINESS WIRE)--Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals’ (Nasdaq: ALNY) new manufacturing facility in Norton, Massachusetts.
Under the terms of the agreement, Jacobs is providing engineering services and procurement for the multi-product facility being built to supply RNA interference-based therapeutics for clinical and commercial needs.
In making the announcement, Jacobs Senior Vice President Global Life Sciences Robert Norfleet stated, “Partnering with Alnylam on this major development that enables the company to realize its goal of becoming a fully integrated, commercial-stage company is an exciting opportunity. We’re proud Alnylam turned to Jacobs as its design partner, and we look forward to delivering a state- of- the-art facility.”
The 200,000 square foot facility is expected to be completed in 2018.
Jacobs is one of the world’s largest and most diverse providers of full-spectrum technical, professional and construction services for industrial, commercial and government organizations globally. The company employs 60,000 people and operates in more than 30 countries around the world. Its Global Life Sciences business is the largest professional services provider to the pharmaceutical and biotechnology industries. For more information, visit www.jacobs.com.
Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2015 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.
